Compare VTRS & CACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | CACI |
|---|---|---|
| Founded | 1961 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 12.9B |
| IPO Year | N/A | 1979 |
| Metric | VTRS | CACI |
|---|---|---|
| Price | $12.85 | $632.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $11.50 | ★ $626.55 |
| AVG Volume (30 Days) | ★ 9.4M | 288.2K |
| Earning Date | 02-26-2026 | 01-21-2026 |
| Dividend Yield | ★ 3.74% | N/A |
| EPS Growth | N/A | ★ 12.06 |
| EPS | N/A | ★ 22.62 |
| Revenue | ★ $14,124,400,000.00 | $8,858,558,000.00 |
| Revenue This Year | N/A | $10.83 |
| Revenue Next Year | $1.18 | $6.73 |
| P/E Ratio | ★ N/A | $27.74 |
| Revenue Growth | N/A | ★ 12.61 |
| 52 Week Low | $6.85 | $318.60 |
| 52 Week High | $13.49 | $632.77 |
| Indicator | VTRS | CACI |
|---|---|---|
| Relative Strength Index (RSI) | 64.61 | 73.74 |
| Support Level | $12.68 | $594.43 |
| Resistance Level | $13.49 | $615.00 |
| Average True Range (ATR) | 0.32 | 17.90 |
| MACD | -0.00 | 9.47 |
| Stochastic Oscillator | 52.31 | 98.19 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.